SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03132779

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortions

Evaluating the effect of intralipid on the natural killer cells

NCT03132779 Recurrent Miscarriage
MeSH:Abortion, Spontaneous Abortion, Habitual
HPO:Spontaneous abortion

1 Interventions

Name: Intralipid

Description: Adose of intralipid given and rechecking NKcells activity
Type: Drug
Group Labels: 1

One armed


Primary Outcomes

Description: NK cells is measured before and after injection of intralipid and is noticed for change in activity

Measure: Change in NK cells activity after injection of intralipid

Time: One week

Purpose: Treatment

Allocation: N/A

Single Group Assignment


There is one SNP

SNPs


1 G20210A

Exclusion Criteria: - Any other diseases causing miscarriage as autoimmune (lupus erythematosus or antiphospholipid antibodies syndrome )or endocrinopathy (diabetes mellitus, thyroid disorders and hyperprolactinaemia)or thrombophilia (factor v leiden mutation, protein c or s deficiency, prothrombin G20210A mutation, antithrombin III deficiency ) or abnormal karyotyping to one or both of parents or previous history of hormonal contraception or intrauterine device usage at last 3 months or any contraindications for intralipid usage. --- G20210A ---



HPO Nodes


HPO: